AstraZeneca’s patent on asthma drug invalidated by US court – Reuters


Reuters

AstraZeneca's patent on asthma drug invalidated by US court
Reuters
NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District …
Actavis launches Pulmicort Respules generic on AZ legal lossPharmaTimes

all 7 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.